Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03

被引：0
作者：
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Quironsalud Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Univ Washington, Sch Med, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[8] Yale Canc Ctr, New Haven, CT USA
[9] Univ Milan, Milan, Italy
[10] IRCCS, European Inst Oncol, Milan, Italy
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Natl Univ Hosp, Seoul, South Korea
[13] AstraZeneca, Gaithersburg, MD USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Daiichi Sankyo, Basking Ridge, NJ USA
[16] Univ Paris Saclay, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1023
引用
收藏
页数：1
相关论文
共 50 条
[31]   Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study [J].
Meric-Bernstam, F. ;
Makker, V. ;
Oaknin, A. ;
Oh, D. Y. ;
Banerjee, S. ;
Martin, A. Gonzalez ;
Jung, K. H. ;
Lugowska, I. ;
Manso, L. M. ;
Manzano, A. ;
Melichar, B. ;
Siena, S. ;
Stroyakovskiy, D. ;
Fielding, A. ;
Ma, Y. ;
Puvvada, S. D. ;
Lee, J. Y. .
ANNALS OF ONCOLOGY, 2023, 34 :S1273-S1274
[32]   Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study [J].
Oh, D-Y. ;
Meric-Bernstam, F. ;
Makker, V. ;
Oaknin, A. ;
Banerjee, S. ;
Gonzalez Martin, A. ;
Jung, K. H. ;
Lugowska, I. ;
Manso, L. M. ;
Manzano, A. ;
Melichar, B. ;
Siena, S. ;
Stroyakovskiy, D. ;
Fielding, A. ;
Ma, Y. ;
Puvvada, S. D. ;
Lee, J-Y. .
ANNALS OF ONCOLOGY, 2023, 34 :S1494-S1495
[33]   COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER [J].
Mudumba, R. ;
Chan, H. ;
Cheng, Y. Y. ;
Wang, C. C. ;
Correia, L. ;
Ballreich, J. ;
Levy, J. .
VALUE IN HEALTH, 2022, 25 (12) :S95-S95
[34]   Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC). [J].
Sledge Jr, George W. ;
Xiu, Joanne ;
Solzak, Jeffrey Peter ;
Mahtani, Reshma L. ;
Oberley, Matthew James ;
Lustberg, Maryam B. ;
Radovich, Milan ;
Spetzler, David .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL)
[35]   Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 [J].
Li, B. T. ;
Planchard, D. ;
Goto, K. ;
Smit, E. F. ;
De langen, J. ;
Goto, Y. ;
Ninomiya, K. ;
Kubo, T. ;
Perol, M. ;
Felip, E. ;
Hayashi, H. ;
Nakagawa, K. ;
Shimizu, J. ;
Nagasaka, M. ;
Pereira, K. M. C. ;
Taguchi, A. ;
Ali, A. ;
Karnoub, M. ;
Yonemochi, R. ;
Janne, P. A. .
ANNALS OF ONCOLOGY, 2023, 34
[36]   Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02) [J].
Oh, Do-Youn ;
Lugowska, Iwona A. ;
Stroyakovskiy, Daniil ;
Jung, Kyung Hae ;
Dumas, Olivier ;
Penkov, Konstantin ;
Dechaphunkul, Arunee ;
Oaknin, Ana ;
Kim, Seung Tae ;
Starling, Naureen ;
Chewaskulyong, Busyamas ;
Charonpongsuntorn, Chanchai ;
Doroshow, Deborah Blythe ;
Hsiao, Sheng-Yen ;
Hung, Yi-Ping ;
Jung, Lindsey ;
Kuptsova-Clarkson, Nataliya ;
Michelini, Flavia ;
Puvvada, Soham D. ;
Meric-Bernstam, Funda .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37]   Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T) [J].
Luis, Ines Maria Vaz Duarte ;
Oh, Coyin ;
Wang, Zhigang ;
Dipiro, Pamela ;
Macrae, Erin Macrae ;
Painter, Corrie ;
Kryukov, Gregory ;
Krop, Ian E. ;
Winer, Eric P. ;
Lin, Nancy U. ;
Wagle, Nikhil .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38]   Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. [J].
Modi, Shanu ;
Andre, Fabrice ;
Krop, Ian E. ;
Saura, Cristina ;
Yamashita, Toshinari ;
Kim, Sung-Bae ;
Tamura, Kenji ;
Chen, Shuquan ;
Suto, Fumitaka ;
Kuwahara, Yusuke ;
Lee, Caleb C. ;
Park, Yeon Hee .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39]   ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd) [J].
Tripathy, Debashish ;
Ali, Kashif ;
Agrawal, Laila ;
Ali, Sami M. ;
Blau, Sibel ;
Block, Margaret ;
Danso, Michael A. ;
Yardley, Denise ;
Andersen, Jay ;
Waks, Adrienne Gropper ;
Jayachandran, Priya ;
Makhlin, Igor ;
Nikolinakos, Petros ;
Zuniga, Richard ;
O'Shaughnessy, Joyce ;
Aung, Sandra ;
Lu, Janice M. ;
Kalinsky, Kevin ;
Gradishar, William John ;
Rugo, Hope S. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40]   Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study [J].
Modi, S. ;
Jacot, W. ;
Iwata, H. ;
Park, Y. H. ;
Vidal Losada, M. J. ;
Li, W. ;
Tsurutani, J. ;
Zaman, K. ;
Ueno, N. T. ;
Prat, A. ;
Papazisis, K. ;
Rugo, H. S. ;
Harbeck, N. ;
Im, S-A. ;
De Laurentiis, M. ;
Orbegoso, C. M. A. ;
Yung, L. ;
Cheng, F-C. ;
Cheng, Y. ;
Cameron, D. A. .
ANNALS OF ONCOLOGY, 2023, 34 :S334-S335
12345